Page 16 - 53-Peptic ulcer diseases (Loét dạ dày)

REFERENCES non-steroidal anti-inflammatory drugs: a randomised trial. Lancet
1. Black J, Duncan W, Durant D. Definition and antagonism of hista- 2002;359:9–13.
mine H2 receptors. Nature 1972;236:365–90. 25. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews
2. Marshall B, Warren J. Unidentified curved bacilli in the stomachs of of the clinical effectiveness and cost-effectiveness of proton pump
patients with gastritis and peptic ulcer. Lancet 1984;1:1311–5. inhibitors in acute upper gastrointestinal bleeding. Health Technol
3. Sonnenberg A. Causes underlying the birth-cohort phenomenon Assess 2007;11:1–164.
of peptic ulcer: analysis of mortality data 1911-2000, England and 26. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper
Wales. Int J Epidemiol 2006;35:1090–7. gastrointestinal bleeding in patients with Helicobacter pylori infec-
4. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global tion who are taking low-dose aspirin or naproxen. N Engl J Med
incidence and prevalence of peptic ulcer disease. Aliment Pharmacol 2001;344:967–73.
Ther 2009;29:938–46. 27. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised con-
5. Li Z, Zou D, Ma X, et al. Epidemiology of peptic ulcer disease: trolled trial of Helicobacter pylori eradication in patients on non-
endoscopic results of the systematic investigation of gastrointestinal steroidal anti-inflammatory drugs. HELP NSAIDs study. Lancet
disease in China. Am J Gastroenterol 2010;105:2570–7. 1998;352:1016–21.
6. Lau JY, Sung J, Hill C, et al. Systematic review of the epidemiology 28. Chan FK, Ching JY, Suen BY, et al. Effects of Helicobacter pylori
of complicated peptic ulcer disease: incidence, recurrence, risk fac- infection on long-term risk of peptic ulcer bleeding in low-dose as-
tors and mortality. Digestion 2011;84:102–13. pirin users. Gastroenterology 2013;144:528–35.
7. Laine L, Yang H, Chang SC, et al. Trends for incidence of hospital- 29. Pecha RE, Prindiville T, Pecha BS, et al. Association of cocaine and
ization and death due to GI complications in the United States from methamphetamine use with giant gastroduodenal ulcers. Am J Gas-
2001-2009. Am J Gastroenterol 2012;107:1190–5. troenterol 1996;91:2523–7.
8. Wu CY, Wu CH, Wu MS, et al. A nationwide population-based 30. Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison
cohort study shows reduced hospitalization for peptic ulcer disease of esophageal and gastroduodenal effects of risedronate and alendro-
associated with H. pylori eradication and proton pump inhibitor nate in postmenopausal women. Gastroenterology 2000;119:631–8.
use. Clin Gastroenterol Hepatol 2009;7:427–31. 31. Conn H, Blitzer B. Nonassociation of adrenocorticosteroid therapy
9. Wang AY, Peura DA. The prevalence and incidence of Helicobacter and peptic ulcer. N Engl J Med 1976;294:473–9.
pylori-associated peptic ulcer disease and upper gastrointestinal 32. Piper J, Ray W, Daugherty J, Griffin M. Corticosteroid use and
bleeding throughout the world. Gastrointest Endosc Clin N Am peptic ulcer disease: role of non-steroidal anti-inflammatory drugs.
2011;21:613–35. Ann Intern Med 1991;114:735–40.
10. Feinstein LB, Holman RC, Yorita Christensen KL, et al. Trends in 33. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neo-
hospitalizations for peptic ulcer disease, United States, 1998-2005. plasia type I and Zollinger-Ellison syndrome: a prospective study
Emerg Infect Dis 2010;16:1410–8. of 107 cases and comparison with 1009 cases from the literature.
11. Sanchez-Delgado J, Gene E, Suarez D, et al. Has H pylori prevalence Medicine (Baltimore) 2004;83:43–83.
in bleeding peptic ulcer been underestimated? A meta-regression. 34. Jensen RT. Gastrointestinal abnormalities and involvement in
Am J Gastroenterol 2011;106:398–405. systemic mastocytosis. Hematol Oncol Clin North Am 2000;14:
12. Olbe L, Hamlet A, Dalenback J, et al. A mechanism by which Helico- 579–623.
bacter pylori infection of the antrum contributes to the development 35. Wong GL, Wong VW, Chan Y, et al. High incidence of mortality
of duodenal ulcer. Gastroenterology 1996;110:1386–94. and recurrent bleeding in patients with Helicobacter pylori-negative
13. El-Omar EM. Mechanisms of increased acid secretion after eradica- idiopathic bleeding ulcers. Gastroenterology 2009;137:525–31.
tion of Helicobacter pylori infection. Gut 2006;55:144–6. 36. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of in-
14. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gas- hibitory effects of the proton pump-inhibiting drugs omeprazole,
trointestinal complications among users of acetaminophen and non- esomeprazole, lansoprazole, pantoprazole, and rabeprazole on hu-
steroidal anti-inflammatory drugs. Epidemiology 2001;12:570–6. man cytochrome P450 activities. Drug Metab Dispos 2004;32:821–7.
15. Wilcox C, Allison J, Benzuly K, et al. Consensus development con- 37. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and pro-
ference on the use of nonsteroidal anti-inflammatory agents, includ- ton pump inhibitors. Basic Clin Pharmacol Toxicol 2004;95:2–8.
ing cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroen- 38. Majumdar SR, Soumerai SB, Farraye FA, et al. Chronic acid-related
terol Hepatol 2006;4:1082–9. disorders are common and underinvestigated. Am J Gastroenterol
16. Sørensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gas- 2003;98:2409–14.
trointestinal bleeding associated with use of low-dose aspirin. Am J 39. Gisbert JP, Calvet X. Helicobacter pylori “test-and-treat” strategy for
Gastroenterol 2000;95:2218–24. management of dyspepsia: a comprehensive review. Clin Transl
17. Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortal- Gastroenterol 2013;4:e32.
ity associated with hospital admission due to severe gastrointesti- 40. Ford AC, Qume M, Moayyedi P, et al. Helicobacter pylori test and
nal events and those associated with nonsteroidal antiinflammatory treat or endoscopy for managing dyspepsia: an individual patient
drug use. Am J Gastroenterol 2005;100:1685–93. data meta-analysis. Gastroenterology 2005;128:1838–44.
18. Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of dam- 41. Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG
age to the gastrointestinal tract from nonsteroidal anti-inflammato- clinical guideline: management of dyspepsia. Am J Gastroenterol
ry drugs. Gastroenterology 2018;154:500–14. 2017;112:988–1013.
19. Fiorucci S, Distrutti E, Santucci L. NSAIDs, Coxinbs CINOD and 42. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of
H2S-releasing NSAIDs: what lies beyond the horizon? Dig Liver Helicobacter pylori infection-the Maastricht V/Florence consensus re-
Dis 2007;39:1043–51. port. European Helicobacter and Microbiota study group and con-
20. Green Jr FW, Kaplan MM, Curtis LE, et al. Effect of acid and pep- sensus panel. Gut 2017;66:6–30.
sin on blood coagulation and platelet aggregation. A possible con- 43. Canga 3rd C, Vakil N. Upper GI malignancy, uncomplicated dys-
tributor prolonged gastroduodenal mucosal hemorrhage. Gastroen- pepsia, and the age threshold for early endoscopy. Am J Gastroen-
terology 1978;74:38–43. terol 2002;97:600–3.
21. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection 44. Feldman M, Burton ME. Histamine2-receptor antagonists: standard
and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a therapy for acid-peptic diseases. N Engl J Med 1990;323:1672–80.
meta-analysis. Lancet 2002;359:14–22. 45. Patel N, Ward U, Rogers MJ, Primrose JN. Night-time or morning
22. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role dosing with H2-receptor antagonists: studies on acid inhibition in
of Helicobacter pylori eradication in the prevention of peptic ulcer in normal subjects. Aliment Pharmacol Ther 1992;6:381–7.
NSAID users. Aliment Pharmacol Ther 2005;21:1411–8. 46. Michaletz-Onody PA. Peptic ulcer disease in pregnancy. Gastroen-
23. Chan FK, Sung JY, Chung SC, et al. Randomised trial of eradication terol Clin North Am 1992;21:817–26.
of Helicobacter pylori before starting non-steroidal anti-inflammatory 47. Cantu TG, Korek JS. Central nervous system reactions to hista-
drug therapy to prevent peptic ulcers. Lancet 1997;350:975–9. mine2-receptor blockers. Ann Intern Med 1991;114:1027–34.
24. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and 48. Wilder-Smith CH, Ernst T, Genonni M, et al. Tolerance to oral
risk of peptic ulcers in patients starting long-term treatment with H2-receptor antagonists. Dig Dis Sci 1990;8:976–83.

819.e1